FDA Brief

FDA warning letters

A warning letter is FDA's formal notice that a company broke the law, usually found during an inspection. The company has 15 working days to reply. Letters that go unanswered lead to seizures, import bans or court orders.

1,276 letters match. Newest first.

  1. Deqing Jiarou Daily Chemical Co., Ltd.

    Deqing Jiarou failed current good manufacturing practice (CGMP) for OTC hand sanitizer, including no methanol testing of ethanol.

    High risk
  2. Higley Industries, Inc.

    FDA warns Higley Industries over CGMP failures in OTC drug manufacturing, including untested ethanol and glycerin.

    High risk
  3. Skull Smash LLC

    Skull Smash LLC sold unapproved, misbranded ammonia inhalant stimulant drugs online, FDA says.

    High risk
  4. Spirochaete Research Labs, LLC aka Scitus Laboratory Products

    FDA warned Spirochaete Research Labs that its Atomic Rhino smelling-salt products are unapproved and misbranded stimulant drugs.

    High risk
  5. Cosmetic Specialty Labs, Inc.

    FDA warned Cosmetic Specialty Labs after an inspection found manufacturing failures in OTC drugs and an unlisted product.

    High risk
  6. Native Salts LLC

    FDA warns Native Salts LLC over unapproved, misbranded ammonia smelling-salt stimulant sold as 'N, Native Salts'.

    High risk
  7. Thai Nakorn Patana Co., Ltd.

    FDA warns Thai Nakorn Patana over manufacturing quality violations, including missing identity and strength testing before release of OTC drugs.

    High risk
  8. Innovative Formulations, LLC dba Insane Labz

    FDA says Innovative Formulations, doing business as Insane Labz, sells Wake the Dead Smelling Salts, an unapproved ammonia stimulant drug, online.

    High risk
  9. Bell International Laboratories, Inc.

    Bell International Laboratories, an OTC drugmaker, was cited for manufacturing rule violations including missing glycerin DEG/EG testing and inadequate quality oversight.

    High risk
  10. ivsupplyclinic.com

    ivsupplyclinic.com sold prescription IV fluids online without prescriptions and with altered labels, FDA says.

    High risk
  11. Colgin, Inc.

    FDA warned Colgin that its OTC drug ChigaRid External Analgesic violated manufacturing quality rules, including expired ingredients and missing tests.

    High risk
  12. LightEyez Limited

    LightEyez eye drops sold in the U.S. were contaminated with microbes, and FDA cited unapproved new drug claims for its eye drops.

    High risk
  13. Amman Pharmaceutical Industries

    FDA warned Amman Pharmaceutical Industries after a 2023 inspection found sterile drug manufacturing and data integrity failures.

    High risk
  14. EzriCare LLC

    EzriCare distributed non-sterile Artificial Tears made by a CMO with CGMP violations, linked to a Pseudomonas outbreak.

    High risk
  15. Delsam Pharma LLC

    Delsam Pharma distributed non-sterile, contaminated artificial tears and eye ointment made by its contract manufacturer, FDA found.

    High risk
  16. Salvacion USA Inc.

    FDA warned Salvacion USA that Covixyl Nasal Spray is an unapproved new drug sold with antiviral claims.

    High risk
  17. Sichuan Deebio Pharmaceutical Co. Ltd.

    FDA warns Sichuan Deebio Pharmaceutical over API manufacturing and data-integrity failures.

    High risk
  18. US Chem Labs

    FDA warned US Chem Labs that it sells unapproved and misbranded Semaglutide, Tirzepatide, and Thymalin drugs online.

    High risk
  19. Synthetix Inc. DBA Helix Chemical Supply

    FDA says Synthetix Inc., doing business as Helix Chemical Supply, sold unapproved and misbranded Semaglutide and Tirzepatide drugs online.

    High risk
  20. Global Life Technologies Corp.

    FDA warns Global Life Technologies over unapproved Nozin Nasal Sanitizer claims, including infection prevention and inside-nostril use.

    High risk
  21. Ningbo Poplar Daily-Use

    FDA warned Ningbo Poplar Daily-Use that its OTC drugs had manufacturing quality failures in testing, component identity checks, and stability data.

    High risk
  22. Madhu Instruments Private Limited

    FDA cites Madhu Instruments in New Delhi for insanitary conditions in sterile drug manufacturing and places it on import alert.

    High risk
  23. QuVa Pharma, Inc.

    FDA warned QuVa Pharma, a sterile drug outsourcing facility in Bloomsbury, NJ, of mold in its cleanest filling area and other CGMP failures.

    High risk
  24. Ehy Holdings, LLC

    FDA warned Ehy Holdings over unupdated drug listings for nicotine patches and creams, calling products misbranded.

    Low
  25. Les Importations Herbasanté Inc.

    Canadian contract maker of homeopathic drugs, including children's products, skipped ingredient testing and process validation, FDA says.

    High risk
  26. Nantong Furuida Packaging Products Co., Ltd.

    Nantong Furuida, an over-the-counter drug manufacturer, failed required manufacturing controls and methanol checks, leading to an FDA import alert.

    High risk
  27. S & J International Enterprises Public Company Limited

    FDA cited S & J International Enterprises for CGMP violations, data integrity failures, and limiting access to records during a drug inspection.

    High risk
  28. Sambrosa Care Inc.

    FDA warns Sambrosa Care that its OTC sweet dreams Night Syrup is an unapproved, misbranded drug with excessive doxylamine dosing.

    High risk
  29. Mei Lan Thailand Co., Ltd.

    Mei Lan Thailand, an API drug manufacturer, refused an FDA inspection and was placed on Import Alert 55-03.

    High risk
  30. Glicerinas Industriales, S.A. de C.V.

    FDA warned Glicerinas Industriales over CGMP failures in repackaged glycerin and propylene glycol, including DEG/EG testing and particulate contamination.

    High risk
  31. Prime Lab LLC

    Prime Lab LLC failed U.S. drug manufacturing quality rules for over-the-counter hand soaps and sanitizers, including raw-material testing and shared toxic equipment.

    High risk
  32. Woorilife & Health

    Woorilife & Health, a South Korean OTC drug maker, failed to test high-risk ingredients for DEG/EG and lacked quality-unit oversight.

    High risk
  33. Jeffrey W. Taub, M.D./Children's Hospital of Michigan

    FDA warns Detroit investigator over pediatric drug trial protocol deviations and lapsed IRB approval.

    High risk
  34. www.trinexpharmacy.com

    FDA warned trinexpharmacy.com for selling unapproved tramadol and misbranded Adderall without prescriptions to U.S. consumers.

    High risk
  35. Curexa – East, LLC dba Curexa

    Curexa - East made compounded drugs under insanitary conditions, with contamination and inadequate cleaning, FDA says.

    High risk
  36. Inopak, Ltd.

    Inopak, Ltd. was warned of CGMP (current good manufacturing practice) violations after inspection: poor quality oversight of contract-made hand sanitizer and missing stability testing.

    High risk
  37. East Fork Cultivars

    East Fork Cultivars sold CBD products as unapproved drugs with COVID-19 and disease-treatment claims, FDA says.

    High risk
  38. Wipro Unza Singapore Private, Limited

    FDA cites Wipro Unza Singapore for refusing OTC hand sanitizer records, leading to import alert.

    High risk
  39. Botanical Be

    FDA says Botanical Be sold three pain products containing hidden diclofenac, an unapproved drug, and made drug claims.

    High risk
  40. Hua Da Trading, Inc.

    FDA warned Hua Da Trading over WeFun, an unapproved drug sold as a supplement that contains undeclared sildenafil.

    High risk
  41. Amazon.com, Inc.

    FDA warned Amazon that energy supplements sold on its site contained undeclared sildenafil or tadalafil, making them unapproved and misbranded drugs.

    High risk
  42. Patcos Cosmetics Pvt. Ltd.

    Patcos Cosmetics, an Indian OTC drug maker, failed to test high-risk ingredients for DEG/EG and lacked quality-unit oversight.

    High risk
  43. Omeza LLC

    FDA warned Omeza LLC over mold, insects and animal waste in drug manufacturing areas and unapproved nonprescription drugs.

    High risk
  44. Anish S. Shah, M.D./Siyan Clinical Research

    FDA warned clinical investigator Dr. Anish Shah that he broke blinding rules in a depression drug study, calling the site's data into question.

    Medium
  45. Dextrum Laboratories Inc.

    FDA found Dextrum Laboratories, an over-the-counter drug contract manufacturer, failed identity testing, toxic glycol checks, water monitoring, and process validation.

    High risk
  46. Colonial Dames Company, Ltd

    FDA warns Colonial Dames of manufacturing violations and unapproved acne drug claims for Oxygenetix.

    High risk
  47. Sudesan Temizlik Urunleri Ve Ambalaj Sanaryi Ticaret Anomin Sirketi

    FDA warns Turkish hand sanitizer maker Sudesan of CGMP violations and adulterated drugs.

    High risk
  48. Novid Group, Inc.

    FDA told Novid Group its OTC nasal spray, novid NASAL SPRAY, is an unapproved new drug and misbranded.

    High risk
  49. Belmont Eyecare LLC

    FDA warned Belmont Eyecare that its website sells unapproved new drug eye drops with treatment claims.

    High risk
  50. Dr. Berne’s Whole Health Products

    Dr. Berne’s MSM eye drops and mist are unapproved new drugs; a tested lot had microbial contamination.

    High risk